# Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma

> **NCT07540702** · NA · RECRUITING · sponsor: **Kasr El Aini Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Melasma
- Facial Melasma

## Interventions

- **BIOLOGICAL:** Injectable Platelet-Rich Fibrin
- **DRUG:** Tranexamic acid 100 mg/mL (Kapron)

## Key facts

- **NCT ID:** NCT07540702
- **Lead sponsor:** Kasr El Aini Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07540702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07540702, "Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07540702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*